--- title: "Silexion Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/286618079.md" datetime: "2026-05-15T21:24:17.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286618079.md) - [en](https://longbridge.com/en/news/286618079.md) - [zh-HK](https://longbridge.com/zh-HK/news/286618079.md) --- # Silexion Therapeutics | 10-Q: FY2026 Q1 Revenue: USD 0 Revenue: As of FY2026 Q1, the actual value is USD 0. EPS: As of FY2026 Q1, the actual value is USD -0.85. EBIT: As of FY2026 Q1, the actual value is USD -2.781 M. Silexion Therapeutics Corp operates as a single segment, with its loss and assets being equivalent to the company’s consolidated net loss and assets. #### Revenue Silexion Therapeutics Corp has not generated any revenue to date. #### Operational Metrics - **Net Loss**: The company incurred a net loss of - $2.7 million for the three months ended March 31, 2026, marking a 58.8% increase from a net loss of - $1.7 million for the same period in 2025. - **Total Operating Expenses**: Total operating expenses increased by 66.6% to $2.749 million for the three months ended March 31, 2026, from $1.65 million in the prior year’s period. - **Research and Development (R&D) Expenses**: R&D expenses increased by $0.8 million, or 133.3%, to $1.4 million for the three months ended March 31, 2026, compared to $0.6 million for the same period in 2025. This increase was primarily due to a $0.7 million rise in subcontractors and consultants expenses for toxicology studies and product development, alongside a $0.1 million increase in share-based compensation expenses. - **General and Administrative (G&A) Expenses**: G&A expenses rose by $0.3 million, or 27.3%, to $1.4 million for the three months ended March 31, 2026, from $1.1 million in the comparable 2025 period. This was mainly driven by a $0.3 million increase in professional services costs and a $0.2 million increase in share-based compensation expenses. - **Financial Expenses (Income), Net**: Financial expenses (income), net, decreased by $0.1 million, or 100%, resulting in $0 million for the three months ended March 31, 2026, compared to $0.1 million for the same period in 2025, primarily due to a reduction in revaluation expenses of financial instruments. #### Cash Flow - **Net Cash Used in Operating Activities**: Net cash used in operating activities increased by $1.1 million, or 44.0%, to - $3.6 million for the three months ended March 31, 2026, from - $2.5 million for the same period in 2025, mainly due to higher prepayments for R&D product development. - **Net Cash Provided by Financing Activities**: Net cash provided by financing activities decreased by $7.3 million, or 98.6%, to approximately $0.1 million for the three months ended March 31, 2026, compared to $7.4 million for the same period in 2025. This significant decrease is attributed to lower capital raised in Q1 2026 ($0.1 million net from ATM sales) compared to Q1 2025, which included $5 million from an offering, $0.9 million from warrant exercises, and $3.3 million from a warrant exercise inducement transaction, partially offset by - $0.7 million in payments for a convertible note. #### Balance Sheet Metrics - **Cash and Cash Equivalents**: As of March 31, 2026, cash and cash equivalents totaled $2.4 million, a decrease from $5.991 million as of December 31, 2025. - **Shareholders’ Equity**: Total shareholders’ equity was $291 thousand as of March 31, 2026, a decrease from $2.603 million as of December 31, 2025. - **Accumulated Deficit**: The accumulated deficit increased to - $57.899 million as of March 31, 2026, from - $55.166 million as of December 31, 2025. - **Related Party Promissory Note**: The outstanding principal amount under the Related Party Promissory Note was $1.633 million as of March 31, 2026, with $0.4 million subsequently converted into ordinary shares, reducing the balance to $1.229 million. - **Israeli Innovation Authority (IIA) Grants**: Silexion Therapeutics Corp received IIA royalty-bearing grants totaling approximately $5.8 million through March 31, 2026, with a total potential royalty amount payable to the IIA of approximately $5.8 million ($6.8 million including interest). #### Strategic Summary and Outlook Silexion Therapeutics Corp’s core business focuses on developing RNA interference (RNAi) therapies for KRAS-driven cancers, with plans to initiate clinical studies for its lead product candidate, SIL204, in the second quarter of 2026, contingent on regulatory clearance. The company expects R&D expenses to continue increasing to support these efforts and potential new product candidates. To ensure ongoing operations and Nasdaq compliance, the company is utilizing an At-The-Market (ATM) Offering Agreement with $12.0 million remaining available and has secured shareholder approval for an increase in authorized share capital and a 1-for-10 reverse share split, expected in late May or early June 2026. Management has concluded there is substantial doubt about the company’s ability to continue as a going concern, as existing cash is sufficient for only several months, necessitating substantial additional funding that may involve significant dilution to current shareholders. ### Related Stocks - [SLXN.US](https://longbridge.com/en/quote/SLXN.US.md) ## Related News & Research - [Is Sarepta Therapeutics (SRPT) Quietly Rewriting Its Risk Profile With New Equity Plans And Q1 Profitability?](https://longbridge.com/en/news/289030593.md) - [Torrid Reports First Quarter 2026 Results and Fiscal 2026 Guidance | CURV Stock News](https://longbridge.com/en/news/288766232.md) - [EXACT Therapeutics Shareholders Approve All Resolutions at 2026 AGM](https://longbridge.com/en/news/289580747.md) - [Ovid Therapeutics Shareholders Back Board and Governance Proposals](https://longbridge.com/en/news/289477648.md) - [Axsome Therapeutics (AXSM) Stock Valuation Update After Strong Recent Momentum](https://longbridge.com/en/news/289575478.md)